Loading chat...

AL SB1

Bill

Status

Introduced

1/13/2026

Primary Sponsor

April Weaver

Click for details

Origin

Senate

2026 Regular Session

AI Summary

  • Reclassifies psychoactive cannabinoids (Delta-8, Delta-9, Delta-10 THC) derived from hemp as Schedule I controlled substances, narrowing the existing hemp exemption to only nonpsychoactive cannabinoids like CBD and CBG

  • Restricts sales of consumable hemp products (tablets, capsules, tinctures, gummies, topicals, suppositories) to licensed pharmacies that obtain annual certification from the Alabama State Board of Pharmacy, effective January 1, 2026

  • Requires all consumable hemp products to use only hemp cultivated within Alabama and mandates the Department of Agriculture and Industries to establish a seed-to-sale tracking system

  • Establishes mandatory laboratory testing protocols for cannabinoid potency, heavy metals, pesticides, microbials, and mycotoxins, with products requiring a certificate of analysis before sale

  • Repeals Act 2025-385, which had assigned regulation of consumable hemp products to the Alabama Alcoholic Beverage Control Board, shifting oversight to the Board of Pharmacy and Department of Agriculture instead

Legislative Description

Controlled substances; regulate sale of nonpsychoactive consumable hemp products by Agriculture Department; require sale of products only in pharmacies; add psychoactive derivatives of hemp as Schedule I drug

Crimes & Offenses

Last Action

Pending Senate Healthcare

1/13/2026

Committee Referrals

Healthcare1/13/2026

Full Bill Text

No bill text available